Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）

NCT05065619 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

128

Enrollment

INDUSTRY

Sponsor class

Stopped Public vaccination of approved ancestral strain COVID-19 vaccines will be terminated soon. And boosters must be dosed after ancestral vaccination approved in Japan. The study was terminated for ethical reason to prioritize the ancestral vaccination.

Conditions

SARS-CoV-2 Infection

Interventions

BIOLOGICAL: MT-2766 High dose (3.75 µg)
DRUG: Placebo
BIOLOGICAL: MT-2766 Low dose

Sponsor

Medicago

Collaborators

[object Object]